These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 15657329)

  • 1. A perspective on US drug reimportation.
    Choudhry NK; Detsky AS
    JAMA; 2005 Jan; 293(3):358-62. PubMed ID: 15657329
    [No Abstract]   [Full Text] [Related]  

  • 2. Risks and benefits of importing prescription medications from lower-income countries.
    Dhalla IA; Detsky AS
    JAMA; 2008 Sep; 300(12):1453-5. PubMed ID: 18812537
    [No Abstract]   [Full Text] [Related]  

  • 3. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It?
    Hyman DA; Silver C
    J Leg Med; 2019; 39(2):137-149. PubMed ID: 31503533
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA recognition of first-world drug regulators as means of relieving U.S. drug shortages.
    Hunnisett-Dritz D
    Am J Health Syst Pharm; 2012 Oct; 69(19):1626, 1628. PubMed ID: 22997113
    [No Abstract]   [Full Text] [Related]  

  • 5. Seizures of Canadian drugs rise as Congress, Customs spar.
    Carreyrou J
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16909501
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical Greed and Its Consequences.
    Jacobs HE
    Conn Med; 2016 May; 80(5):315-6. PubMed ID: 27328583
    [No Abstract]   [Full Text] [Related]  

  • 7. Thalidomide and beyond: some recommendations regarding public policies toward the ethical drug industry.
    Schifrin LG
    Int J Health Serv; 1974; 4(1):147-55. PubMed ID: 4829893
    [No Abstract]   [Full Text] [Related]  

  • 8. Where does drug importation stand now?
    Guglielmo WJ
    Med Econ; 2005 Mar; 82(6):42, 44, 46. PubMed ID: 15869085
    [No Abstract]   [Full Text] [Related]  

  • 9. How parallel trade affects drug policies and prices in Canada and the United States.
    Hollis A; Ibbott P
    Am J Law Med; 2006; 32(2-3):193-217. PubMed ID: 16927610
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA chief attacks Canada's drug price controls.
    Webster P
    Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
    [No Abstract]   [Full Text] [Related]  

  • 11. Remarks delivered at the Food and Drug Law Institute's 48th Annual Conference.
    Enzi MB
    Food Drug Law J; 2005; 60(2):103-6. PubMed ID: 16097090
    [No Abstract]   [Full Text] [Related]  

  • 12. An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?
    Minssen T; Kesselheim AS; Darrow JJ
    Nat Biotechnol; 2019 Jan; 37(1):21-22. PubMed ID: 30605154
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceuticals and medical devices: business practices.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2014 Dec; ():1-38. PubMed ID: 25771555
    [No Abstract]   [Full Text] [Related]  

  • 14. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 15. Canadian drugs: panacea or problem?
    State Legis; 2004 Jun; 30(6):9. PubMed ID: 15179953
    [No Abstract]   [Full Text] [Related]  

  • 16. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT
    J Contemp Health Law Policy; 2006; 22(2):383-408. PubMed ID: 17117702
    [No Abstract]   [Full Text] [Related]  

  • 17. United States prescription drug crisis. Reimportation of Canadian prescription drugs is not the answer.
    Martin J
    J Leg Med; 2006 Dec; 27(4):477-92. PubMed ID: 17162683
    [No Abstract]   [Full Text] [Related]  

  • 18. Deterring the importation of counterfeit pharmaceutical products.
    Stearn DW
    Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
    [No Abstract]   [Full Text] [Related]  

  • 19. Analysis of pharmaceutical product diversion and the gray market: cheaper drugs, but at what cost?
    Dooley K; Sullivan JA
    Health Care Law Mon; 2010 Oct; 2010(10):2-8. PubMed ID: 21302589
    [No Abstract]   [Full Text] [Related]  

  • 20. The case for less, not more, US FDA regulation.
    Vernon JA; Golec JH
    Pharmacoeconomics; 2011 Aug; 29(8):637-40. PubMed ID: 21732703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.